JUPITER, Fla., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology…
Significant progress made and well positioned for future growthLONDON, UK / ACCESSWIRE / September 13, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF),…
Phase 1 part of combined Phase 1/2 study assessed comprehensive series of flu vaccine candidates, featuring up to eight separate…
In the phase 3 trial, a randomized double blind and placebo-controlled pivotal study, 1,212 mild or moderate COVID-19 patients were…
Encouraging interim data support the potential of IO102-IO103 in combination with pembrolizumab as first-line treatment in non-small cell lung cancerNEW…
Vancouver, British Columbia--(Newsfile Corp. - September 12, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence"…
Clinical data show robust immune responses across multiple circulating variants, including EG.5, FL.1.5.1, and BA.2.86Updated vaccine to be available in…
Evaxion is the first organization to validate an AI model that outcompetes state-of-the-art vaccine developmentEvaxion's AI model predicts vaccine efficacy…
CAMBRIDGE, MA / ACCESSWIRE / September 8, 2023 / Moderna, Inc. (Nasdaq:MRNA) has been notified that TRC Capital Investment Corporation…
Table 1 Table 1 Chart 1 Chart 1 Chart 2 Chart 2 Table 2 Table 2All study objectives were met,…